Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Incyte logo
IncyteINCY
$6.28M-14.1%
PVL
Palvella TherapeuticsPVLA
-$32K-114%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.4M+81.2%
TTR
Turn Therapeutics Inc.TTRX
$5.58K-89.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$245.3M-44.6%

Segments

By segment

See full
Reportable Segment-$157K-885%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income (expense):
Interest income2,2792,0764,5544,613
Interest expense(3,406)(3,029)(7,774)(6,011)
Other income (expense), net(157)20(177)213
Total other income (expense)(1,284)(933)(3,397)(1,185)
Income (loss) before income taxes15,145(15,544)3,943(40,325)
Provision for income taxes136342229621
Net income (loss)$15,009$(15,886)$3,714$(40,946)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s other income, net (note 6)?
Arcutis Biotherapeutics, Inc. (ARQT) reported other income, net (note 6) of -$157K in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Arcutis Biotherapeutics, Inc.'s other income, net (note 6) decreased by 885.0% year-over-year, from $20K to -$157K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Arcutis Biotherapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude